News: Umeå, 8 July, 2022. Lipum (publ) is preparing for the start of its first in human phase 1 clinical trial and the team is now strengthened with Dr. Helena Bergström that has been recruited as chief medical officer (CMO).
Dr. Helena Bergström is an experienced clinician that previously also has been involved in research of sex-and gender differences in medicine, drug metabolism and lipidology. She graduated from Uppsala University in 1996 and holds a PhD in medical science. While working as a clinical pharmacology physician for AstraZeneca R&D, Helena was engaged in the planning and execution of first in human studies in neuroscience and cardiometabolic diseases. She has also been co-investigator in numerous studies from phase 1 to 4, and in different therapeutic areas.
Helena will be the physician in charge of the upcoming clinical trial and in connection with her appointment, Lipum's organisation has changed slightly and Professor Olle Hernell, board member and one of the company's founders, will instead take on the role of Senior Medical Advisor.
“Dr Bergström has valuable and extensive experience in pharmacology and clinical trials. Her strong drive and commitment will also certainly contribute to the success of our clinical development. She will be an important cog in our team, and I am delighted to welcome Helena.” says CEO Einar Pontén.
For further information, please contact:
Einar Pontén, CEO
E-post: einar.ponten@lipum.se
Mobile: +46 70 578 34 95
Web: www.lipum.se
About Lipum
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: ca@gwkapital.se, phone: +46 8 503 000 50.